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The development of the breast is exquisitely sensitive to
interactions between the epithelium and stroma. Experimental
evidence indicates that a reduction in signalling between any
of the stromal cell types (fibroblasts, macrophages, endo-
thelial cells and adipocytes) results in reduced or absent
breast development [1], although all interactions appear to be
orchestrated by the epithelial cell oestrogen receptor alpha
[2]. The epithelial–stromal interactions that occur in tumours
are less well characterised but there is no doubt there is
expansion of the stroma as well as of the epithelium during
tumour development [3,4]. Recent data indicate that the
prognosis after breast cancer diagnosis relates to stromal
type, and experimental and clinical studies directed at
modifying the stroma (for example, angiogenesis inhibitors)
suggest that the stroma is a target for therapy that is worthy
of further exploration
Studies of separately microdissected breast stroma and
epithelium from normal lobules compared with ductal
carcinoma in situ (DCIS) and invasive cancer indicate that
extensive changes in gene expression in both the epithelial
and stromal compartments occur during cancer development.
These data strongly support the hypothesis that performing
microdissections can be less optimal for gene expression
profiling studies or to exclude cancers with a prominent
stroma. Some array-based studies have had a requirement of
more than 50% of cancer cells in the biopsies taken for array
profiling; this may result in exclusion of biologically important
cancers.
Compared with the intralobular stroma of the normal breast
lobule, Ma and colleagues reported that 2,338 genes were
upregulated and 1,234 genes were downregulated in the
stroma of DCIS [5]. A further 76 genes were upregulated and
229 genes were downregulated in the stroma of invasive
tumours, indicating that most of the changes had occurred in
DCIS – suggesting that paracrine and endocrine influences
are driving stroma formation rather than cell interactions,
since the basement membrane is largely intact in DCIS. In a
similar study examining stroma separated from the epithelium,
Casey and colleagues demonstrated that the major changes
of gene expression were upregulation of genes for the
extracellular matrix and proteases in the stroma and
downregulation of cytoskeletal proteins such as keratins,
tubulins and adhesion molecules leading to increased cell
motility in the tumour epithelium [6].
Invasive tumours have been likened to ‘wounds that do not
heal’ [7]. In order to establish whether tumours induced gene
expression similar to wounds, Chang and colleagues investi-
gated whether they expressed the genes induced by serum in
fibroblasts (the equivalent of wounding) [8,9]. The expression
of 422 selected genes changed by serum in tumours was
associated with a poor prognosis, whereas tumours with no
change tended to have a good prognosis. In this study,
although the genes were produced in serum-treated
fibroblasts, they could have been expressed in epithelial cells
of the tumours studied.
In order to assess the prognostic and predictive significance
of genes strictly of stromal origin, Finak and colleagues
isolated stroma from normal lobules and tumours by laser
capture microdissection, and derived a 26-gene expression
signature that was a poor prognostic indicator irrespective of
breast tumour subtype and standard prognostic indicators
and that also indicated resistance to standard treatments
[10]. The stromal signature, however, has been described to
be associated with a basal type of breast cancer in three
independent datasets, including the Canadian study [11].
Other gene signatures derived from the whole tumour and
searched for potential stromal genes were also able to detect
a poor prognosis signature [12] and to detect a stromal
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signature that indicated failure to respond to neoadjuvant
5-fluorouracil, epirubicin, and cyclophosphamide chemo-
therapy [13].
More recently two groups have demonstrated downregulation
of a protein (caveolin-1) that acts as a scaffold protein in cell
surface pits or caveolae (important for signal transduction
amongst other functions) in the stroma of invasive tumours
and DCIS of poor prognosis [14-16]. Previous studies by the
Lisanti group have shown that caveolin-1 is downregulated in
fibroblasts during transformation and that recombinant
expression of caveolin-1 in oncogenically transformed cells
abrogates anchorage-independent growth, therefore biologi-
cally underpinning the observations in breast tumour stroma
[17,18].
The stroma, as shown by mammographic density, may also
be changed in the normal breast during treatment with
tamoxifen. We analysed stromal change over 12 to
18 months in the IBIS I tamoxifen prevention trial and
demonstrated that women who had a tamoxifen-induced
reduction of breast density were less likely to develop breast
cancer [19]. This is consistent with the effect of tamoxifen in
the rat breast, where it reduced proteolytic enzyme activity
and extracellular matrix degradation [20].
These data outlines above indicate that certain types of
tumour stoma may be related to the tendency of tumours to
metastasise and related to resistance of the metastases to
systemic therapy. There is evidence that factors secreted by
the primary tumour such as osteopontin [21] and hypoxia-
induced lysyl oxidase [22], and even systemically synthesised
oestrogen [23,24], can influence seeding of metastasis even
before tumour cells migrate – leading to the concept of the
pre-metastatic niche [25,26].
Since the primary tumour is removed at surgery, the major
target for therapy is the metastatic site (or sites harbouring
dormant cells). Information concerning the effect on primary
tumour or normal breast stroma can come from neoadjuvant
and preventive studies, respectively. Little is known concern-
ing the configuration of stroma at metastatic sites and
whether or not it is similar to stroma in the primary tumour.
Studies on tumour epithelium in matched primary tumours
and metastases indicate that the phenotype of tumour
epithelial cells can change, and thus the stroma might also
change – indicating the important need for matched-pair
studies on stroma as well as the epithelium [27]. Recent
reviews have highlighted the potential of the tumour stroma
as a target for therapy [28-30]. Antiangiogenic therapies and
possibly bisphosphonates [31] are effective agents in current
use targeting the stroma. There is great interest in targeting
other cells, including tumour-associated fibroblasts [32,33],
macrophages and other immune cells [34,35], and the
extracellular matrix, since there is strong evidence that
extracellular matrix-associated cells, in contradistinction to
isolated cells, may be resistant to therapy [36]. There is also
interest in using altered or armed mesenchymal stem cells
reinfused into the patient, which are likely to home to sites of
injury such as tumours [37,38]. Alterations in the tumour
stroma appear to be able to induce resistance to standard
therapies as outlined above. Study of the mechanisms
involved and ways to circumvent them are potentially
important with respect to increased cure rates in women with
breast cancer [36,39].
In conclusion, the tumour stroma in breast has been
neglected in many studies. Upcoming prevention, diagnostic
and therapy strategies and studies should be carried out in
an unbiased way, allowing analyses of the stromal compart-
ment in addition to the classical investigations of the epithelial
cancer component.
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